Details

Autor(en) / Beteiligte

• Grund, Andrea
• Szaroszyk, Malgorzata
• Korf‐Klingebiel, Mortimer
• Malek Mohammadi, Mona
• Trogisch, Felix A
• Schrameck, Ulrike
• Gigina, Anna
• Tiedje, Christopher
• Gaestel, Matthias
• Kraft, Theresia
• Hegermann, Jan
• Batkai, Sandor
• Thum, Thomas
• Perrot, Andreas
• Remedios, Cris dos
• Riechert, Eva
• Völkers, Mirko
• Doroudgar, Shirin
• Jungmann, Andreas
• Bauer, Ralf
• Yin, Xiaoke
• Mayr, Manuel
• Wollert, Kai C
• Pich, Andreas
• Xiao, Hua
• Katus, Hugo A
• Bauersachs, Johann
• Müller, Oliver J
• Heineke, Joerg

Titel

TIP 30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation

Ist Teil von

• EMBO molecular medicine, 2019-10, Vol.11 (10)

Ort / Verlag

Frankfurt: John Wiley & Sons, Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Wiley Online Library

Beschreibungen/Notizen

• Pathological cardiac overload induces myocardial protein synthesis and hypertrophy, which predisposes to heart failure. To inhibit hypertrophy therapeutically, the identification of negative regulators of cardiomyocyte protein synthesis is needed. Here, we identified the tumor suppressor protein TIP30 as novel inhibitor of cardiac hypertrophy and dysfunction. Reduced TIP30 levels in mice entailed exaggerated cardiac growth during experimental pressure overload, which was associated with cardiomyocyte cellular hypertrophy, increased myocardial protein synthesis, reduced capillary density, and left ventricular dysfunction. Pharmacological inhibition of protein synthesis improved these defects. Our results are relevant for human disease, since we found diminished cardiac TIP30 levels in samples from patients suffering from end‐stage heart failure or hypertrophic cardiomyopathy. Importantly, therapeutic overexpression of TIP30 in mouse hearts inhibited cardiac hypertrophy and improved left ventricular function during pressure overload and in cardiomyopathic mdx mice. Mechanistically, we identified a previously unknown anti‐hypertrophic mechanism, whereby TIP30 binds the eukaryotic elongation factor 1A (eEF1A) to prevent the interaction with its essential co‐factor eEF1B2 and translational elongation. Therefore, TIP30 could be a therapeutic target to counteract cardiac hypertrophy.